Finally, a more general role for GSK3B in drug resistance can be proposed given that several studies indicated GSK3B as an actionable target for the treatment of drug-resistant carcinomas derived not only from colon but also from kidney [72], pancreas [73,74,75], endometrium [76] and for glioblastomas [77,78,79]. This evidence concerns the gene GSK3B and carcinoma.